Really thought this would have got more attention even in PM
$CureVac (CVAC.US)$ GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Bln
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
OneNightOnly : rightfully a good news, but no volumns yet
Trytosaveabit OP OneNightOnly : Maybe so low because of all the restructuring and laying off people? The bad helping keep the good down? Or maybe just because of closing early today? Or waiting for market open? Just not used to seeing 1.5 billion deal not get attention right away? Hehehe
OneNightOnly : probably many US traders take 1/2 day off so nobody is keen to look at this, maybe delayed action till next Monday.
Trytosaveabit OP OneNightOnly : Yeah Friday or Monday entered my thoughts as well! But I will keep a eye on it! Hehehe
Bully Bill 100 : the volume is there now lol
Trytosaveabit OP Bully Bill 100 : It’s come up yup! But still not what I was expecting? GL
101567573 Trytosaveabit OP : I would like to ask why is this good news still declining?
Trytosaveabit OP 101567573 : IMO it’s from shorts pushing price down on low volume! And some just selling because of analysts cutting the price target for now!
101567573 Trytosaveabit OP : Understood! Thanks for the answers! Studying hard
Arrayfunction 101567573 : I am new to stocks, but work in the bio-tech industry. This is good news for the insiders, but likely means the company is dead.
The way small bio-techs work is a group of investors buy the rights to one or a couple potential drug candidates, they burn through cash like crazy to run the necessary trials to show a drug is safe and effective enough to be patentable.
Then one of two outcomes:
The drug candidate succeeds and they get to sell the patent to big pharma who actually have the resources to market and sell it. The insiders have a quick ROI dance party then immediately kill the company because it is no longer useful.
The drug candidate fails, there is no dance party, and the insiders kill the company because it's no longer useful.
There will be times a bio-tech has more than one drug candidate in play and part of their business will stay open to work on the other ones, but not always. Either because insiders have made enough money the risk is not worth it, or the company simply runs out of cash before they have anything worth selling.